Croci Stefania, Nicoletti Giordano, Landuzzi Lorena, Palladini Arianna, Chiarini Francesca, Nanni Patrizia, Lollini Pier-Luigi, De Giovanni Carla
Cancer Research Section, Department of Experimental Pathology, University of Bologna, I-40126 Bologna, Italy.
Oncol Rep. 2007 Aug;18(2):451-6.
To study the role of the chemokine receptor CCR7 in the metastatic process, a murine CCR7 gene was transduced in two mammary cancer cell lines with different origins and molecular features; TS/A, derived from a spontaneous mammary cancer of BALB/c strain, and N202.1A, derived from a HER-2/neu transgenic mammary cancer (FVB background) and characterized by a high expression of HER-2/neu. Transduced CCR7 conferred to mammary cancer cells a chemotactic response towards CCL21 (a CCR7 ligand), but did not consistently affect in vitro growth properties. In vivo, CCR7-engineered cells gave rise to tumors in syngeneic hosts with growth rates similar to or slightly lower than the controls and with similar patterns of spontaneous metastases. When injected directly intravenously to study the late post-intravasation phases of metastasis, CCR7-engineered cells showed a strongly decreased lung colonizing ability. Such an effect was observed both with HER-2/neu-positive and -negative mammary cancer cells. When used as a prophylactic vaccine, CCR7-transduced cell vaccine succeeded in the long-term control of mammary tumorigenesis in 25% of the HER-2/neu transgenic females, suggesting an increased immunogenicity of CCR7-engineered cells.
为研究趋化因子受体CCR7在转移过程中的作用,将小鼠CCR7基因转导至两种具有不同起源和分子特征的乳腺癌细胞系中;TS/A源自BALB/c品系的自发性乳腺癌,N202.1A源自HER-2/neu转基因乳腺癌(FVB背景),其特征为HER-2/neu高表达。转导的CCR7赋予乳腺癌细胞对CCL21(一种CCR7配体)的趋化反应,但并未持续影响体外生长特性。在体内,经CCR7改造的细胞在同基因宿主中形成肿瘤,其生长速率与对照组相似或略低于对照组,且具有相似的自发转移模式。当直接静脉注射以研究转移的血管内后期阶段时,经CCR7改造的细胞显示出肺定植能力大幅下降。在HER-2/neu阳性和阴性乳腺癌细胞中均观察到这种效应。当用作预防性疫苗时,经CCR7转导的细胞疫苗成功地长期控制了25%的HER-2/neu转基因雌性小鼠的乳腺肿瘤发生,表明经CCR7改造的细胞免疫原性增强。